Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

One Or Multiple Investigational Sites, Japan Clinical Trials

A listing of One Or Multiple Investigational Sites, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (4667) clinical trials

This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib.   The primary objective of the study is to ...

Phase

The purpose of this research study is to compare the efficacy and safety of a investigational medication versus Enbrel in people with plaque psoriasis.

Phase

ActivMed Practices and Research is looking for volunteers to participate in a nationwide study on chronic plaque psoriasis. If you are 18 or older, and have been diagnosed with chronic plaque psoriasis for at least 6 months, you may qualify for this study.

Phase

A 52-week, multicenter, randomized, double-blind study of secukinumab (300mg) to demonstrate efficacy as assessed by psoriasis area and severity index and investigator's global assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis.

Phase

This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially ...

Phase

Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes, an umbrella term used to describe disorders relating to the ineffective production of red blood cells, white blood cells, and/or platelets. Ranging in severity from mild (asymptomatic) to severe, anemia can result in ...

Phase

Primary Outcome Measures: Event-free survival (EFS) [ Time Frame: Approximately 3 years ] Time from randomization to death from any cause, progressive disease (PD), failure to achieve complete response (CR) or partial response (PR), or start of new antineoplastic therapy due to efficacy concerns, whichever occurs first     Secondary Outcome Measures: Complete response ...

Phase

Patient Inclusion Criteria: 18+ years of age Diagnosis of stable plaque psoriasis Mild to moderate on trunk and/or limbs Patient Exclusion Criteria: Current diagnosis of guttate, erythrodermic or pustular psoriasis

Phase

Patient Inclusion Criteria: 18+ years of age Diagnosis of stable plaque psoriasis Moderate to severe Covering at least 10% of total body surface area Patient Exclusion Criteria: Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis

Phase